Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC)from Health Canada for its generic Semaglutide injection.
Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with type 2 diabetes.
Dr. Reddy’s Laboratories gains Health Canada approval for generic Semaglutide, enhancing diabetes treatment access for ...
Dr. Reddy’s Laboratories Ltd. announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic ...
Dr Reddy's Labs gets Health Canada approval for generic semaglutide injection: Our Bureau, Bengaluru Wednesday, April 29, 2026, 11:35 Hrs [IST] Dr Reddy’s Laboratories has recei ...
Dr. Reddy’s Laboratories (DRL) has secured Health Canada's first-ever generic Semaglutide approval, targeting the world's ...
A recent Indian Phase III randomized open-label study has demonstrated that Sun Pharma’s injectable semaglutide is ...
Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, ...
DRL is the first company to receive market authorisation for a generic semaglutide injection in Canada. It is the first ...
With the API is entirely produced in house by Dr. Reddy's, OneSource Specialty Pharma to manufacture generic Ozempic version ...
Hosted on MSN
Canada approves first generic semaglutide in G7
Health Canada has approved Dr. Reddy’s Laboratories’ generic version of semaglutide, making Canada the first G7 nation to authorise such a product. The drug, used for once-weekly treatment of Type 2 ...
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), shares stumbled Wednesday, despite the company receiving a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. Thus, Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results